Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Grete Semb

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Arthritis Research & Therapy|July 5, 2017
Cardiovascular disease risk profiles in inflammatory joint disease entitiesGrunde Wibetoe, Eirik Ikdahl, Silvia Rollefstad, et al.
RMD Open|October 12, 2018
Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR projectEirik Ikdahl, Silvia Rollefstad, Grunde Wibetoe, et al.
International Journal of Cardiology|July 16, 2018
Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseasesEirik Ikdahl, Grunde Wibetoe, Silvia Rollefstad, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 21, 2024
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023Juan Tamargo, Stefan Agewall, Claudio Borghi, et al.
European Heart Journal. Acute Cardiovascular Care|December 27, 2022
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyKonstantin A Krychtiuk, Ingo Ahrens, Heinz Drexel, et al.
Circulation|November 23, 2005
Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled studyLars Gullestad, Thor Ueland, Jan G Fjeld, et al.
European Journal of Preventive Cardiology|August 12, 2025
Cardiovascular risk factors management in older adults: a clinical consensus statement from the European Association of Preventive Cardiology of the ESC and the ESC Council for Cardiology PracticeRoberto F E Pedretti, Riccardo Asteggiano, Andreas B Gevaert, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 5, 2026
Cardiovascular pharmacotherapy in year in 2025Juan Tamargo, Stefan Agewall, Giuseppe Ambrosio, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 9, 2025
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024Juan Tamargo, Stefan Agewall, Giuseppe Ambrosio, et al.
RMD Open|February 2, 2026
Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Virginia Pascual-Ramos, Miguel A Gonzalez-Gay, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Arthritis Research & Therapy|July 5, 2017
Cardiovascular disease risk profiles in inflammatory joint disease entitiesGrunde Wibetoe, Eirik Ikdahl, Silvia Rollefstad, et al.
RMD Open|October 12, 2018
Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR projectEirik Ikdahl, Silvia Rollefstad, Grunde Wibetoe, et al.
International Journal of Cardiology|July 16, 2018
Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseasesEirik Ikdahl, Grunde Wibetoe, Silvia Rollefstad, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 21, 2024
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023Juan Tamargo, Stefan Agewall, Claudio Borghi, et al.
European Heart Journal. Acute Cardiovascular Care|December 27, 2022
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyKonstantin A Krychtiuk, Ingo Ahrens, Heinz Drexel, et al.
Circulation|November 23, 2005
Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled studyLars Gullestad, Thor Ueland, Jan G Fjeld, et al.
European Journal of Preventive Cardiology|August 12, 2025
Cardiovascular risk factors management in older adults: a clinical consensus statement from the European Association of Preventive Cardiology of the ESC and the ESC Council for Cardiology PracticeRoberto F E Pedretti, Riccardo Asteggiano, Andreas B Gevaert, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 5, 2026
Cardiovascular pharmacotherapy in year in 2025Juan Tamargo, Stefan Agewall, Giuseppe Ambrosio, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 9, 2025
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024Juan Tamargo, Stefan Agewall, Giuseppe Ambrosio, et al.
RMD Open|February 2, 2026
Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Virginia Pascual-Ramos, Miguel A Gonzalez-Gay, et al.
Pageof 12